Gyre Therapeutics (GYRE) EBIAT (2016 - 2025)
Historic EBIAT for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $5.9 million.
- Gyre Therapeutics' EBIAT rose 10784.31% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 11412.47%. This contributed to the annual value of $17.9 million for FY2024, which is 12093.82% up from last year.
- Latest data reveals that Gyre Therapeutics reported EBIAT of $5.9 million as of Q3 2025, which was up 10784.31% from $1.6 million recorded in Q2 2025.
- Gyre Therapeutics' 5-year EBIAT high stood at $51.6 million for Q2 2022, and its period low was -$101.0 million during Q4 2023.
- In the last 5 years, Gyre Therapeutics' EBIAT had a median value of $1.6 million in 2025 and averaged -$7.4 million.
- Its EBIAT has fluctuated over the past 5 years, first crashed by 45361.46% in 2021, then surged by 35909.27% in 2022.
- Gyre Therapeutics' EBIAT (Quarter) stood at -$20.3 million in 2021, then tumbled by 37.23% to -$27.9 million in 2022, then plummeted by 261.95% to -$101.0 million in 2023, then skyrocketed by 100.56% to $569000.0 in 2024, then skyrocketed by 943.23% to $5.9 million in 2025.
- Its EBIAT stands at $5.9 million for Q3 2025, versus $1.6 million for Q2 2025 and $3.7 million for Q1 2025.